Destum Partners

Bridging the Gap Between Science and Business

Uncategorized

By

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform – BDDSTM – to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets 

CAMBRIDGE, Mass. and DAEJEON, South Korea | March 27, 2023 – BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDSTM), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets. 

[Read more…] about BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

By

Destum Partners Strengthens Their Management Team By Appointing Matt Vanderberg And Tom Filipczak To Managing Director

CHARLOTTE, N.C., May 11 /PRNewswire/ — Destum Partners continues to grow their infrastructure by expanding their management team. Both Tom Filipczak and Matt Vanderberg were formerly Business Development Directors with Destum Partners, but have now been promoted to Managing Director. Destum Partners strives to advance innovative technology within the life sciences industry through analytic services to improve decision making, and through advisory services to ensure collaborations.